Crossmark

A long-term survivor of metastatic neuroendocrine prostate cancer treated with multimodal therapy: genetic consideration from next-generation sequencing

Crossref DOI link: https://doi.org/10.1007/s13691-021-00482-2

Published Online: 2021-04-13

Published Print: 2021-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hongo, Hiroshi

Kosaka, Takeo https://orcid.org/0000-0002-4371-4594
Nakatsuka, Seishi

Oya, Mototsugu
Funding

Funding for this research was provided by:

the Ministry of Education, Culture, Sports, Science, and Technology of Japan (#17K16813, #17K11158)

the Takeda Science Foundation
License Information

Text and Data Mining valid from 2021-04-13

Version of Record valid from 2021-04-13
More Information

Article History

Received: 2 February 2021

Accepted: 31 March 2021

First Online: 13 April 2021

Declarations

:

: The authors declare that they have no conflict of interests.

: This study was approved by the Ethics Committee of the Keio University Hospital (Approval Numbers 20150285, 20160084). Written informed consent for the study was obtained from the patient.

Document is current

Any future updates will be listed below